BioLife Sciences (OTC: BLFE) has announced that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on hemp products. According to the update, the company will focus on new and innovative product infusions centered around North American-grown, third-party tested industrial hemp with the intention to provide consumers with an array of new and more effective options. “We are so thrilled that BioLife will be focusing on this stream of business focusing on products in the marketplace, which are not only disruptors, but that are beneficial and useful products for consumers to seek out,” said Nika Jaksic, COO of BioLife Sciences. “Some view this market as already being over-saturated. However, at BioLife, we are confident that this sector will continue to grow in the coming years, and consumers as a whole are moving towards more holistic approaches such as CBD, CBG and CBN. Consumers are continuing to become more aware of the benefits of CBD, and other cannabinoids, for not just humans, but for pets too.”
To view the full press release, visit https://ibn.fm/uxYBf
About BioLife Sciences Inc.
BioLife Sciences specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technologies. One of BioLife Sciences’ core building block strategies is to develop, partner with and assist innovative companies with the commercialization of leading-edge technologies. For more information about the company, visit www.BioLifeSciences.com.
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork